


AMENDMENTS TO THE CLAIMS


The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) Crystalline solid pantoprazole characterized by a powder X-ray diffraction pattern having peaks at 6.6, 13.2, 13.7, 15.7, 23.1, and 23.4 ± 0.2 $^{\circ}2\theta$.
2. (currently amended) The crystalline solid pantoprazole of claim 1 further having peaks in the powder X-ray diffraction pattern at 20.1, 20.9, 25.9, 27.5, and 29.1 ± 0.2 $^{\circ}2\theta$.
3. (currently amended) The crystalline solid pantoprazole of claim 1 having a powder X-ray diffraction pattern substantially as depicted as follows: ~~in Figure 1.~~




4. (original) The crystalline solid pantoprazole of claim 1 having an infrared spectrum with bands at 1385, 1264, 1244, 1180, and 1027 cm^{-1} .


5. (currently amended) The crystalline solid pantoprazole of claim 4 having an infrared spectrum substantially as depicted as follows: in ~~Figure 2~~.



- 6-12. (withdrawn)
13. (original) Crystalline solid pantoprazole characterized by a powder X-ray diffraction pattern having peaks at 5.8, 7.5, 9.3, 15.0, 22.0, and $22.6 \pm 0.2^\circ 2\theta$.
14. (original) The crystalline solid pantoprazole of claim 13 further having peaks in the powder X-ray diffraction pattern at 17.3, 18.6, 19.4, 20.8, 24.0, 24.8, and $25.5 \pm 0.2^\circ 2\theta$.
15. (currently amended) The crystalline solid pantoprazole of claim 13 having a powder X-ray diffraction pattern substantially as depicted as follows: in ~~Figure 3~~.



16. (original) The crystalline solid pantoprazole of claim 13 having an infrared spectrum having bands at 3195, 1196, and 1584 at cm^{-1} .
17. (currently amended) The crystalline solid pantoprazole of claim 16 having an infrared spectrum substantially as depicted as follows: ~~in Figure 4.~~



18. (original) The crystalline solid pantoprazole of claim 13 having a melting endotherm at about 143°C to about 146°C.
- 19-40. (withdrawn)
41. (currently amended) A pharmaceutical composition comprising the crystalline solid pantoprazole of ~~any of claims 1, or 13, and 26~~ and a pharmaceutical excipient.
42. (original) The pharmaceutical composition of claim 41 that is a solid.
43. (original) The pharmaceutical composition of claim 42 that is a tablet.
44. Canceled.

45. (currently amended) A method of inhibiting gastric acid secretion in the stomach of a patient comprising administering to the patient the crystalline solid pantoprazole of ~~any of claims 1, or 13, and 26.~~

46-50. (withdrawn)